Navigation Links
OU researcher developing novel therapy for Alzheimer's disease
Date:7/8/2010

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patientan approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

Peter J. Heinzelman, an associate professor in the Department of Chemical, Biological and Mechanical Engineering, recently received a $75,000 grant from the Oklahoma Center for the Advancement of Science and Technology to pursue this research, which includes the development of a library of biopharmaceutical proteases for public use.

Heinzelman's previous research led to the idea that proteases, or proteins that degrade other proteins, would be more effective as a therapy for Alzheimer's disease than existing approaches. The brain is surrounded by a barrier of cells that allows glucose to pass through but is resistant to drug molecules and therapeutic proteins.

By virtue of a single protease molecule able to degrade thousands of the plaque molecules, these proteases should be capable of delivering a catalytic benefit even if only small amounts pass through the cell barrier surrounding the brain.

"Digestive enzymes are promiscuous," says Heinzelman. "We can create catalytic proteases that attack the beta-amyloid plaque that cause neurons in the brain to die. Current therapies use amyloid-binding antibodies that are created by the body or injected to get rid of the plaque, but these antibodies used to attack the problematic Abeta molecules can only bind one time and clear one Abeta molecule, then they are done."

The delivery system is problematic, too. Heinzelman suggests an approach that addresses both therapeutic efficacy and delivery. He wants to re-engineer an existing technology to link proteases with "ferrying" antibodies that can encourage passage of the proteases from the circulation side across the brain cell barrier and into the brain tissue. This approach has been demonstrated in the laboratory.

Another aspect of the OCAST grant is the development of a library of proteases that will be made freely available and could become a powerful tool for the scientific community. Heinzelman is working with researchers from the University of Wisconsin-Madison and the Oklahoma Medical Research Foundation on this grant.


'/>"/>

Contact: Jana Smith
jana.smith@ou.edu
405-325-1322
University of Oklahoma
Source:Eurekalert

Related medicine news :

1. Researchers identify factors behind blood-making stem cells
2. Parkinsons Transplant Mystery Solved, Researchers Say
3. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
4. Researchers suggest new paradigm for breast cancer screening
5. Of lice and man: Researchers sequence human body louse genome
6. AcademyHealth honors leading health services researchers
7. UCLA researchers, US military collaborate to open center for traumatic brain injury
8. Texas A&M researcher explains how embryo fights retroviral infection
9. UC San Diego researcher awarded $5.3 million for breast cancer survivorship study
10. UCSD researchers receive $2.5 million in new stem cell grants
11. Researchers find key to getting estrogens benefits without cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: